Literature DB >> 23929841

Lactate dehydrogenase and hemolysis in sickle cell disease.

Gregory J Kato, Seyed Mehdi Nouraie, Mark T Gladwin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23929841      PMCID： PMC3739033          DOI： 10.1182/blood-2013-05-505016

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia.

Authors:  Samir K Ballas; Mary Jane Marcolina
Journal:  Transfusion       Date:  2006-01       Impact factor: 3.157

2.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 3.  Lactate dehydrogenase and hemolysis in sickle cell disease.

Authors:  Samir K Ballas
Journal:  Blood       Date:  2013-01-03       Impact factor: 22.113

4.  Lactic acid dehydrogenase activity and plasma hemoglobin elevations in sickle cell disease.

Authors:  C L Neely; T Wajima; A P Kraus; L W Diggs; L Barreras
Journal:  Am J Clin Pathol       Date:  1969-08       Impact factor: 2.493

5.  Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease.

Authors:  Ashaunta Tumblin; Anitaben Tailor; Gerard T Hoehn; A Kyle Mack; Laurel Mendelsohn; Lita Freeman; Xiuli Xu; Alan T Remaley; Peter J Munson; Anthony F Suffredini; Gregory J Kato
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

6.  High lactate dehydrogenase levels at admission for painful vaso-occlusive crisis is associated with severe outcome in adult SCD patients.

Authors:  Katia Stankovic Stojanovic; Olivier Steichen; Guillaume Lefevre; Claude Bachmeyer; Virginie Avellino; Gilles Grateau; Robert Girot; François Lionnet
Journal:  Clin Biochem       Date:  2012-08-08       Impact factor: 3.281

7.  The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe.

Authors:  Mehdi Nouraie; Janet S Lee; Yingze Zhang; Tamir Kanias; Xuejun Zhao; Zeyu Xiong; Timothy B Oriss; Qilu Zeng; Gregory J Kato; J Simon R Gibbs; Mariana E Hildesheim; Vandana Sachdev; Robyn J Barst; Roberto F Machado; Kathryn L Hassell; Jane A Little; Dean E Schraufnagel; Lakshmanan Krishnamurti; Enrico Novelli; Reda E Girgis; Claudia R Morris; Erika Berman Rosenzweig; David B Badesch; Sophie Lanzkron; Oswaldo L Castro; Jonathan C Goldsmith; Victor R Gordeuk; Mark T Gladwin
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

8.  Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease.

Authors:  Eduard J van Beers; Marianne C L Schaap; René J Berckmans; Rienk Nieuwland; Augueste Sturk; Frederiek F van Doormaal; Joost C M Meijers; Bart J Biemond
Journal:  Haematologica       Date:  2009-10-08       Impact factor: 9.941

9.  Serum-alpha-hydroxybutyrate dehydrogenase levels in sickle-cell disease and sickle-cell crisis.

Authors:  J M White; F Billimoria; M A Muller; L R Davis; C E Stroud
Journal:  Lancet       Date:  1978-03-11       Impact factor: 79.321
  9 in total
  4 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

Review 2.  Biomechanics and biorheology of red blood cells in sickle cell anemia.

Authors:  Xuejin Li; Ming Dao; George Lykotrafitis; George Em Karniadakis
Journal:  J Biomech       Date:  2016-11-12       Impact factor: 2.712

3.  Iron Chelation Reduces DNA Damage in Sickle Cell Anemia.

Authors:  Rawan S Al-Khateeb; Hanan S Althagafy; Mohammad Zaki ElAssouli; Dunya A Nori; Mohammed AlFattani; Salwa A Al-Najjar; Turki Al Amri; Anwar M Hashem; Steve Harakeh; Nawal Helmi
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

Review 4.  Critical Role of Hemopexin Mediated Cytoprotection in the Pathophysiology of Sickle Cell Disease.

Authors:  Rani Ashouri; Madison Fangman; Alicia Burris; Miriam O Ezenwa; Diana J Wilkie; Sylvain Doré
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.